Experimental drug aims to boost radiation against brain cancer

NCT ID NCT02993146

Ongoing Symptom relief Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an oral drug called ropidoxuridine (IPdR) combined with whole brain radiation in people whose cancer has spread to the brain. The goal is to find the safest dose and see if the drug makes radiation more effective at killing tumor cells. About 11 adults with brain metastases are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM MALIGNANT SOLID NEOPLASM METASTATIC MALIGNANT NEOPLASM IN THE BRAIN

Contacts and locations

Locations

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030, United States
Ben Taub General Hospital

Houston, Texas, 77030, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242, United States
University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Weisberg Cancer Treatment Center

Farmington Hills, Michigan, 48334, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.